홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Sincalide

HCID 9833444
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
25126-32-3
표준 SMILES
CSCC[C@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@@H](N)CC(=O)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
InChIKey
IZTQOLKUZKXIRV-YRVFCXMDSA-N
분자식
C49H62N10O16S3
평균 분자량
1,143.3 g/mol
단동위원소 질량
1,142.35073945

개요

Sincalide is an oligopeptide.

이름 및 식별자

우선 이름
Sincalide
IUPAC
(3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-oxobutanoic acid
영어명
Sincalide
분자식
C49H62N10O16S3
분자량
1143.27

이름 및 동의어

Sincalide25126-32-3CCK-8KinevacSincalidaCCK-8SSincalidumSyncalideSQ 19844cholecystokinin C-terminal octapeptideDTXSID7048617CCK C-terminal octapeptide
이름 더 보기
Sincalide AcetateSincalidabs50003Sinkalite
SQ-19844M03GIQ7Z6PH-Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2Caerulein, 1-de(5-oxo-L-proline)-2-de-L-glutamine-5-L-methionine-Cholecystokinin octapeptideDTXCID4028543L-alpha-Aspartyl-O-sulfo-L-tyrosyl-L-methionylglycyl-L-tryptophyl-L-methionyl-L-alpha-aspartyl-L-phenylalaninamideL-Aspartyl-L-tyrosyl-L-methionylglycyl-L-tryptophyl-L-methionyl-L-aspartylphenyl-L-alaninamide hydrogen sulfate (ester)

데이터베이스 식별자

CAS
25126-32-3
PubChem CID
9833444
DTXSID
DTXSID7048617
ChEMBL
CHEMBL1121
ChEBI
CHEBI:135946
UNII
M03GIQ7Z6P
EC Number
246-639-0
Nikkaji
J236.060H

물성

구조 계산 물성보충 중

XLogP
-2.6
극성 표면적
486 Ų
수소 결합 공여자 수
13
수소 결합 수용자 수
19
회전 가능 결합 수
33
무거운 원자 수
78
형식 전하
0
복잡도
2,180

실험 및 물리화학적 성질

Human Drugs · 3건

Breast Feeding; Lactation; Milk, Human; Gastrointestinal Hormones; Cholecystokinin; Diagnostic Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

물리화학적 성질

녹는점
193 °C · >193°C (dec.)
밀도
1.44 · 1.440±0.06 g/cm3(Predicted)
저장 조건
-20 °C · -20°C
용해도
0.05 M · 0.05 M 수산화암모늄: 1 mg/mL, 투명, 무색
물리적 상태
가루
산도 계수 (pKa)
-4.17 · -4.17±0.18(Predicted)
색상
회백색
수용성
10 °C에서 · 10°C에서 물 1g/L에 용해됩니다.
Merck
13 · 13,8617
BRN
5231801 · 5231801
InChIKey
IZTQOLKUZKXIRV-IVVJSLGPSA-N

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

독성 정보

Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Sincalide

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

안전 데이터

wgk
3
HS 번호
2933998090
safety_code
22-24/25
F 고인화성물질
8-10-21
스토리지 클래스
11 - Combustible Solids

화학 및 산업

약리 정보

ATC Code · 2건

V - Various

QV - Various

Protein BindingLimited information is available on the protein binding of sincalide.
Pharmacodynamics · 1건

Following an intravenous (bolus) injection of 0.02 mcg/kg of sincalide, maximal contraction of the gallbladder occurred in 5 to 15 minutes. Sincalide reduced gallbladder radiographic size by at least 40%, generally considered satisfactory contraction.

Mechanism of Action · 1건

When injected intravenously, sincalide produces a substantial reduction in gallbladder size by causing this organ to contract. The evacuation of bile that results is similar to that which occurs physiologically in response to endogenous cholecystokinin. Like cholecystokinin, sincalide stimulates pancreatic secretion; concurrent administration with secretin increases both the volume of pancreatic secretion and the output of bicarbonate and protein (enzymes) by the gland. This combined effect of secretin and sincalide permits the assessment of specific pancreatic function through measurement and analysis of the duodenal aspirate.

Biological Half-LifeLimited information is available on the half-life of sincalide.
Metabolism/MetabolitesLimited information is available on the metabolism of sincalide.
FDA Pharmacological Classification · 6건

M03GIQ7Z6P

SINCALIDE

Chemical Structure [CS] - Cholecystokinin

Established Pharmacologic Class [EPC] - Cholecystokinin Analog

Sincalide is a Cholecystokinin Analog.

SINCALIDE

Absorption, Distribution and Excretion · 3건

The intravenous (bolus) administration of sincalide causes a prompt contraction of the gallbladder that becomes maximal in 5 to 15 minutes, as compared with the stimulus of a fatty meal which causes a progressive contraction that becomes maximal after approximately 40 minutes.

Limited information is available on the route of elimination of sincalide

Limited information is available on the volume of distribution of sincalide.

응용 분야 · 2건

용도Sincalide is used in the biological studies in the preparation of opioid receptors agonistic and CCK receptor antagonistic activity.

일반 설명It was thought originally that cholecystokinin and pancreozyminwere two different hormones. Cholecystokinin wasthought to be responsible for contraction of the gallbladder,whereas pancreozymin was believed to induce secretion ofpancreatic enzymes. It is now clear that both actions arecaused by a single 33-residue polypeptide, referred to ascholecystokinin–pancreozymin (CCK-PZ). CCK-PZ is secretedin the blood in response to the presence of food in theduodenum, especially long-chain fatty acids. The fiveCOOH-terminal amino acid residues are identical with thosein gastrin. The COOH-terminal octapeptide retains full activityof the parent hormone.

상·하류 제품 정보

상류 원료

황산

관련 반응

1건
반응 기록 만들기
HRID 1464588 반응식
HRID 1464588반응물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트